This aspect is particularly topical, since different agents that either specifically target the alternative pathway or prevent C3 activation unselectively via the three activation pathways are being tested in patients with C3G and Ig-MPGN (Figs 1 and 3 and Box 1) [41]. Here, C3 is linked to complement 3 glomerulopathy.